NCCN 13th Annual Congress: Hematologic Malignancies™


This agenda is subject to change. Faculty will be updated as confirmed.

  • Saturday, September 22, 2018
    7:00 AM  -  8:00 AM
    Registration, Breakfast, and Exhibits
    8:00 AM  -  8:05 AM
    Opening Remarks
    8:05 AM  -  9:05 AM
    Patient Case Studies and Panel Discussion: Leukemia and Myeloproliferative Neoplasms
    9:05 AM  -  9:35 AM
    Optimizing TKI Therapy for Chronic Phase CML: Sequencing of TKI Therapy and Treatment-free Remission
    9:35 AM  -  10:05 AM
    Prognostic Significance of Mutations in Myeloproliferative Neoplasms
    10:05 AM  -  10:30 AM
    Break and Exhibits
    10:30 AM  -  11:15 AM
    Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
    11:15 AM  -  11:45 PM
    Current Approaches to Initial Treatment of Newly Diagnosed Multiple Myeloma
    11:45 AM  -  12:15 PM
    Emerging Options and Sequencing Therapies for Relapsed Multiple Myeloma
    12:15 PM  -  1:30 PM
    Lunch and Exhibits
    12:25 PM  -  1:25 PM
    Symposium: Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas
    This optional session is open to all health care providers attending the NCCN Hematologic Malignancies Congress; pre-registration is not required. CME/CNE/CPE available. Seating is limited and on a first-come, first-seated basis.

    This activity is supported by educational grants from AstraZeneca and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

    This symposium is accredited and supported separately from all other educational sessions on this agenda.
    1:30 PM  -  2:00 PM
    Management of Bone Health in Patients with Hematologic Malignancies
    2:00 PM  -  3:00 PM
    Patient Case Studies and Panel Discussion: Lymphoma
    3:00 PM  -  3:30 PM
    Updates in the Management of CLL: Histologic Transformation and Relapsed/Refractory Disease
    3:30 PM  -  3:55 PM
    Break and Exhibits
    3:55 PM  -  4:25 PM
    Updates to Front-line Therapy in Hodgkin Lymphoma
    4:25 PM  -  4:55 PM
    Emerging Options for the Management of Relapsed/Refractory Hodgkin Lymphoma
    4:55 PM  -  5:00 PM
    Closing Remarks